Payment overview · 2025
General Payments
$1,738.18
60 reported records · 29 companies
Healthcare provider profile · identity verified
Mark Anderson, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · JACKSON, MS · NPI 1922202415
Verified facts
What the public records show
CMS Open Payments records show Mark Anderson, MD received $1,738.18 in general payments during 2025 across 60 reported records.
ABIOMED accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ubrelvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $570.75 | 32.8% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $103.56 | 6.0% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $102.93 | 5.9% | 5 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $85.65 | 4.9% | 4 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $83.51 | 4.8% | 4 | 2025 |
| Telix Pharmaceuticals | Unresolved — no canonical attribution shown | $60.37 | 3.5% | 1 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.01 | 3.0% | 2 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $45.01 | 2.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $44.25 | 2.5% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $41.91 | 2.4% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $41.20 | 2.4% | 2 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $40.02 | 2.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.95 | 2.2% | 2 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $37.57 | 2.2% | 2 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $37.36 | 2.1% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $34.67 | 2.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.44 | 1.9% | 1 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $32.39 | 1.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.20 | 1.8% | 1 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $30.81 | 1.8% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.45 | 1.8% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $29.16 | 1.7% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.75 | 1.3% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.91 | 1.2% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $20.30 | 1.2% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.88 | 1.0% | 1 | 2025 |
| Acrotech Biopharma Inc. | Unresolved — no canonical attribution shown | $17.79 | 1.0% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $16.75 | 1.0% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.63 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,401.20 | 58 |
| Travel and Lodging | $336.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $85.65 | 4 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $81.22 | 4 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $60.31 | 3 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $52.01 | 2 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $52.01 | 2 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $52.01 | 2 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $45.01 | 2 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $43.53 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $41.91 | 2 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $40.02 | 2 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $39.98 | 2 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| BENEFIX Normalized: benefix |
Biological | PFIZER INC. | $33.44 | 1 | 2025 |
Source payment records
|
|||||
| HYMPAVZI Normalized: hympavzi |
Drug | PFIZER INC. | $33.44 | 1 | 2025 |
Source payment records
|
|||||
| XYNTHA Normalized: xyntha |
Biological | PFIZER INC. | $33.44 | 1 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $32.39 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $32.39 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $30.81 | 2 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $30.45 | 2 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $29.16 | 1 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $27.49 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Merck Sharp & Dohme LLC | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| Voranigo Normalized: voranigo |
Drug | SERVIER PHARMACEUTICALS LLC | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| ALUNBRIG Normalized: alunbrig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| Venclexta Normalized: venclexta |
Biological | Genentech USA, Inc. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| BELEODAQ Normalized: beleodaq |
Drug | Acrotech Biopharma Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| Oncaspar Normalized: oncaspar |
Drug | SERVIER PHARMACEUTICALS LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 200 | 42 |
| Gabapentin | Gabapentin | 185 | 41 |
| Topiramate | Topiramate | 133 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 103 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 24 |
| Lacosamide | Lacosamide | 96 | 19 |
| Zonisamide | Zonisamide | 68 | 11 |
| Lamotrigine | Lamotrigine | 64 | 14 |
| Pregabalin | Pregabalin | 63 | 14 |
| Donepezil Hcl | Donepezil Hcl | 57 | 14 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 50 | suppressed |
| Baclofen | Baclofen | 46 | 12 |
| Aimovig Autoinjector | Erenumab-Aooe | 45 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 45 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 38 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Ubrelvy | Ubrogepant | 34 | suppressed |
| Dexamethasone | Dexamethasone | 33 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 33 | 14 |
| Emgality Pen | Galcanezumab-Gnlm | 32 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Levetiracetam Er | Levetiracetam | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 18 | suppressed |
| Briviact | Brivaracetam | 18 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 16 | suppressed |
| Qulipta | Atogepant | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Xcopri | Cenobamate | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,738.18 · 60 records | ABIOMED | ALUNBRIG, AYVAKIT, BELEODAQ, BENEFIX, BESREMI, BRAFTOVI, BRUKINSA, CABOMETYX, DARZALEX, Enhertu, GIVLAARI, GOMEKLI, Gavreto, HYMPAVZI, ICLUSIG, IMBRUVICA, INQOVI, JAKAFI, JEMPERLI, KEYTRUDA, LONSURF, LUTATHERA, MEKTOVI, OJJAARA, Oncaspar, Orserdu, PLUVICTO, PYRUKYND, REBLOZYL, Rezlidhia, SARCLISA, SCEMBLIX, TALVEY, TAVALISSE, TECVAYLI, TEVIMBRA, TUKYSA, ULTOMIRIS, Venclexta, Voranigo, WELIREG, XPOVIO, XYNTHA, ZEJULA, ZEPZELCA, ZYNLONTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error